Merck & Co., Inc. Target of Unusually High Options Trading (NYSE:MRK)

Key Points

• Merck experienced unusually large options activity on Friday — investors bought 672,962 call options, roughly a 1,339% increase versus the average daily call volume.
• Several analysts have raised price targets recently, leaving Merck with a consensus rating of "Moderate Buy" and a consensus target price of $126.81.
• Merck beat quarterly estimates with $2.04 EPS (vs. $2.01 expected) and $16.4B in revenue, set FY2026 guidance of $5.00–$5.15 EPS, and announced a quarterly dividend of $0.85 (2.9% yield, ex-dividend March 16).

Merck & Co., Inc. (NYSE:MRK - Get Free Report) saw unusually large options trading on Friday. Investors acquired 672,962 call options on the company. This is an increase of approximately 1,339% compared to the average daily volume of 46,777 call options.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Citigroup upped their price target on Merck & Co., Inc. from $115.00 to $120.00 and gave the stock a "neutral" rating in a report on Wednesday, February 4th. Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an "overweight" rating in a research report on Thursday. TD Cowen upped their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a research note on Tuesday, January 20th. Scotiabank increased their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a "sector outperform" rating in a report on Thursday, December 4th. Finally, Bank of America lifted their target price on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a "buy" rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $126.81.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK traded down $0.30 during midday trading on Friday, reaching $115.61. 7,058,649 shares of the company's stock were exchanged, compared to its average volume of 9,573,144. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The company's 50 day simple moving average is $115.08 and its two-hundred day simple moving average is $99.37. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The firm has a market capitalization of $285.84 billion, a PE ratio of 15.88, a price-to-earnings-growth ratio of 2.24 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion for the quarter, compared to analysts' expectations of $16.19 billion. During the same quarter in the previous year, the firm posted $1.72 earnings per share. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.'s dividend payout ratio is currently 46.70%.

Insider Buying and Selling

In other news, EVP Jennifer Zachary sold 121,573 shares of the company's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Michael Williams sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $121.91, for a total value of $609,550.00. Following the completion of the transaction, the executive vice president directly owned 30,838 shares in the company, valued at $3,759,460.58. The trade was a 13.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.13% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the 4th quarter worth about $25,000. Darwin Wealth Management LLC increased its position in Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company's stock valued at $26,000 after acquiring an additional 216 shares in the last quarter. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth about $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $26,000. Finally, Kilter Group LLC acquired a new position in shares of Merck & Co., Inc. during the second quarter worth approximately $27,000. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.